ABSTRACT
Antithrombotics have been used for decades and have vastly improved outcomes for patients with acute coronary syndromes, percutaneous coronary interventions, deep venous thrombosis, pulmonary embolus, and thrombus formation due to atrial fibrillation. The traditional antithrombotics warfarin and heparin have complex pharmacokinetics and pharmacodynamics, which need to be appreciated for optimal pharmacotherapy to occur. Over the past several years, new antithrombotics have given us new treatment choices with pharmacokinetic and pharmacodynamic advantages over traditional agents.
